Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease

Experimental Neurology

Volumn 203, Issue 2, 2007, Pages 415-422

  Scheller, Dieter ^a   Chan, Piu ^b   Li, Qin ^c   Wu, Tao ^b   Zhang, Renling ^b   Guan, Le ^b   Ravenscroft, Paula ^c   Guigoni, Celine ^d   Crossman, Alan R ^c   Hill, Michael ^c   Bezard, Erwan ^d  

^a Schwarz Pharma AG   (Germany)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Williams House   (United Kingdom)

^d CNRS   (France)

Author keywords

125I nortropane; 99mTc TRODAT; Autoradiography; Dopamine agonist; Dopamine transporter; SPECT; Striatum; Substantia nigra pars compacta

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IODINE 125; NORTROPANE DERIVATIVE; ROTIGOTINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MACACA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; TREATMENT DURATION;

ANIMALS; AUTORADIOGRAPHY; DOPAMINE AGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MPTP POISONING; NEOSTRIATUM; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE, SECONDARY; RADIOPHARMACEUTICALS; TETRAHYDRONAPHTHALENES; THIOPHENES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; TYROSINE 3-MONOOXYGENASE;

EID: 33846469933     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.08.026     Document Type: Article

References (47)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 94 (1946) 239-247
2. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., and Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9435-9440
3. Bezard E., Imbert C., Deloire X., Bioulac B., and Gross C. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 766 (1997) 107-112
4. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Bioulac B., Brotchie J.M., and Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. J. Neurosci. 21 (2001) 6853-6861
5. Bezard E., Dovero S., Belin D., Duconger S., Jackson-Lewis V., Przedborski S., Piazza P.V., Gross C.E., and Jaber M. Enriched environment confers resistance to MPTP and cocaine: involvement of dopamine transporter and neurotrophic factors. J. Neurosci. 23 (2003) 10999-11007
6. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C.E., and Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 9 (2003) 762-767
7. Bezard E., Gerlach I., Moratalla R., Gross C.E., and Jork R. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol. Dis. 23 (2006) 77-86
8. Brotchie J.M., and Fox S.H. Quantitative assessment of dyskinesias in subhuman primates. Mov. Disord. 14 Suppl. 1 (1999) 40-47
9. Cho S., Neff N.H., and Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic l-amino acid decarboxylase by dopaminergic drugs. Eur. J. Pharmacol. 323 (1997) 149-157
10. Connor B., Kozlowski D.A., Schallert T., Tillerson J.L., Davidson B.L., and Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6 (1999) 1936-1951
11. Connor B., Kozlowski D.A., Unnerstall J.R., Elsworth J.D., Tillerson J.L., Schallert T., and Bohn M.C. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp. Neurol. 169 (2001) 83-95
12. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. Temporospatial progression of the loss of dopaminergic neurons in the substantia nigra in Parkinson's disease. Mov. Disord. 12 Suppl. 1 (1997) 73
13. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain-I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D-28K immunohistochemistry. Brain 122 (1999) 1421-1436
14. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain-II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (1999) 1437-1448
15. Dawson T.M., and Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. (2002) 1058-1061 (Suppl.)
16. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 252 Suppl. 4 (2005) IV37-IV42
17. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., and Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004) 2498-2508
18. Fahn S., and Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1 (2004) 139-154
19. François C., Yelnik J., and Percheron G. A stereotaxic atlas of the basal ganglia in macaques. Brain Res. Bull. 41 (1996) 151-158
20. Guigoni C., Dovero S., Aubert I., Qin L., Bioulac B.H., Bloch B., Gurevich E.V., Gross C.E., and Bezard E. Levodopa-induced dyskinesia in MPTP-treated macaque is not dependent of the extent and pattern of the nigrostrial lesion. Eur. J. Neurosci. 22 (2005) 283-287
21. Hill M.P., Ravenscroft P., Bezard E., Crossman A.R., Brotchie J.M., Michel A., Grimee R., and Klitgaard H. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J. Pharmacol. Exp. Ther. 310 (2004) 386-394
22. Imbert C., Bezard E., Guitraud S., Boraud T., and Gross C.E. Comparison between eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey. J. Neurosci. Methods 96 (2000) 71-76
23. Jaber M., Jones S., Giros B., and Caron M.G. The dopamine transporter: a crucial component regulating dopamine transmission. Mov. Disord. 12 (1997) 629-633
24. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
25. Joyce J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90 (2001) 231-259
26. Joyce J.N., Smutzer G., Whitty C.J., Myers A., and Bannon M.J. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov. Disord. 12 (1997) 885-897
27. Joyce J.N., Woolsey C., Ryoo H., Borwege S., and Hagner D. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol. 2 (2004) 22
28. Kupsch A., Sautter J., Schwarz J., Riederer P., Gerlach M., and Oertel W.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 741 (1996) 185-196
29. Le W.D., and Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease?. Drugs Aging 18 (2001) 389-396
30. Marek K., Seibyl J., Shoulson I., Holloway R., Kieburtz K., McDermott M., Kamp C., Shinaman A., Fahn S., Lang A., Weiner W., and Welsh M. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
31. Meissner W., Hill M.P., Tison F., Gross C.E., and Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of clinical trials and animal models. Trends Pharmacol. Sci. 25 (2004) 249-253
32. Meissner W., Prunier C., Guilloteau D., Chalon S., Gross C.E., and Bezard E. Time course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol. Neurobiol. 28 (2003) 87-96
33. Miller R.G. Simultaneous Statistical Inference (1981), Springer, New York
34. Morrish P.K. REAL and CALM: what have we learned?. Mov. Disord. 18 (2003) 839-840
35. MSCCH1 I.S.R. Evaluation of the Neuroprotective Effects of Rotigotine in the Progressive MPTP-Lesioned Macaque Model of Parkinson's Disease (Dose Finding) (2004), Schwarz Biosciences, Monheim
36. Nair V.D., Olanow C.W., and Sealfon S.C. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem. J. 373 (2003) 25-32
37. Olanow C.W. The scientific basis for the current treatment of Parkinson's disease. Annu. Rev. Med. 55 (2004) 41-60
38. Pearce R.K., Jackson M., Smith L., Jenner P., and Marsden C.D. Chronic l-dopa administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix jacchus). Mov. Disord. 10 (1995) 731-740
39. Prunier C., Bezard E., Mantzarides M., Besnard J.C., Baulieu J.L., Gross C.E., Guilloteau D., and Chalon S. Presymptomatic diagnosis of experimental parkinsonism with 123I-PE2I SPECT. NeuroImage 19 (2003) 810-816
40. Ravina B., Eidelberg D., Ahlskog J.E., Albin R.L., Brooks D.J., Carbon M., Dhawan V., Feigin A., Fahn S., Guttman M., Gwinn-Hardy K., McFarland H., Innis R., Katz R.G., Kieburtz K., Kish S.J., Lange N., Langston J.W., Marek K., Morin L., Moy C., Murphy D., Oertel W.H., Oliver G., Palesch Y., Powers W., Seibyl J., Sethi K.D., Shults C.W., Sheehy P., Stoessl A.J., and Holloway R. The role of radiotracer imaging in Parkinson disease. Neurology 64 (2005) 208-215
41. Schapira A.H. Neuroprotection and dopamine agonists. Neurology 58 (2002) S9-S18
42. Scheller D.K.A. Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist being investigated in Parkinson's disease. Mov. Disord. 21 (2006) S75
43. Strait K.A., and Kuczenski R. Dopamine autoreceptor regulation of the kinetic state of striatal tyrosine hydroxylase. Mol. Pharmacol. 29 (1986) 561-569
44. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., and Redmond D.E. Behavioral effects of MPTP administration in the vervet monkey, a primate model of Parkinson's disease. In: Woodruff M.L., and Nonneman A. (Eds). Toxin-Induced Models of Neurological Disorders (1994), Plenum Press, New York 139-151
45. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., and Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2837-2842
46. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., and Brooks D.J. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54 (2003) 93-101
47. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771